Status:

COMPLETED

Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).

Lead Sponsor:

Daiichi Sankyo

Conditions:

Venous Thromboembolism

Deep Vein Thrombosis (DVT)

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots...

Eligibility Criteria

Inclusion

  • Male or female subjects older than the minimum legal adult age (country specific);
  • Acute symptomatic proximal DVT and/or symptomatic PE confirmed at the site by appropriate diagnostic imaging;
  • Able to provide written informed consent

Exclusion

  • thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT and/or PE;
  • More than 48 hours pre-treatment with anticoagulant therapy prior to randomization;
  • Calculated Creatinine clearance (CrCL) \< 30 mL/min;
  • significant liver disease (e.g., acute hepatitis, chronic active hepatitis, cirrhosis) or alanine transaminase (ALT) \>\\= 2 times the upper limit of normal (ULN), or total bilirubin (TBL) x 1.5 times the ULN;
  • patients with active cancer for whom long term treatment with (LMW) heparin is anticipated;
  • active bleeding or high risk for bleeding contraindicating treatment with (LMW) heparin or warfarin;
  • chronic treatment with non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs);
  • treatment with aspirin in a dosage of more than 100 mg/per day or dual antiplatelet therapy;
  • concurrent treatment with potent P-gp inhibitors;
  • subjects with any condition that, as judged by the investigator, would place the subject at increased risk of harm if he/she participated in the study

Key Trial Info

Start Date :

October 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2013

Estimated Enrollment :

8292 Patients enrolled

Trial Details

Trial ID

NCT00986154

Start Date

October 1 2009

End Date

April 1 2013

Last Update

March 5 2019

Active Locations (454)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 114 (454 locations)

1

Investigational Site 7103

Mobile, Alabama, United States, 36608

2

Investigational Site 7132

Montgomery, Alabama, United States, 36116

3

Investigational Site 7126

Phoenix, Arizona, United States, 85006

4

Investigational Site 7139

Little Rock, Arkansas, United States, 72205